Halobetasol propionate 0.01% and tazarotene 0.045% combination therapy (HP/TAZ) is effective for treating localized moderate-to-severe psoriasis, according to a publication in the Journal of Drugs in Dermatology.
Researchers completed 2 post hoc analyses of large, double-blind trials examining the efficacy of HP/TAZ combination therapy for clinically meaningful outcomes.
Investigator’s Global Assessment and body surface area involvement were used to evaluate plaque qualities and disease extent. A clinically meaningful outcome was defined as a 75% reduction in the Investigator’s Global Assessment and body surface area involvement combination score. Patients (N=418) included in both studies were randomly assigned to receive either HP/TAZ lotion or a placebo. Data was collected at baseline then again at weeks 2, 4, 6, 8, and 12.
The treatment arm experienced significant improvements in disease severity from week 2 to week 12 (P <.001, for all). By week 8, patients in the treatment arm experienced a 51.9% mean improvement in Investigator’s Global Assessment scores and a 9.21% mean improvement in body surface area involvement score (P <.001) from baseline. At week 12, patients in the treatment arm experienced a 46.6% mean improvement in Investigator’s Global Assessment scores and a 7.92% mean improvement in body surface area involvement score (P <.001) from baseline.
The researchers noted that “[p]ost-treatment return of psoriatic signs and symptoms is common with topical therapies, and can be a significant concern for patients.” However, reductions in symptoms with HP/TAZ lotion were “sustained 4 weeks post-treatment,” and were able to conclude that “a fixed combination [HP/TAZ] lotion provided rapid and sustained relief of psoriatic signs and symptoms.”
Disclosures Several authors report multiple associations with pharmaceutical companies. Please see the original reference for a full list of authors’ disclosures.
Blauvelt A, Green LJ, Lebwohl MG, et al. Efficacy of a once-daily fixed combination halobetasol (0.01%) and tazarotene (0.045%) lotion in the treatment of localized moderate-to-severe plaque psoriasis. J Drugs Dermatol. 2019; 18(3):297-299.
This article originally appeared on Dermatology Advisor